Alkermes plc

NasdaqGS:ALKS Stock Report

Market Cap: US$4.8b

Alkermes Future Growth

Future criteria checks 0/6

Alkermes's revenue and earnings are forecast to decline at 0.7% and 12.6% per annum respectively. EPS is expected to decline by 14.7% per annum. Return on equity is forecast to be 15.9% in 3 years.

Key information

-12.6%

Earnings growth rate

-14.7%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate-0.7%
Future return on equity15.9%
Analyst coverage

Good

Last updated05 Dec 2024

Recent future growth updates

Recent updates

We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt

Dec 17
We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt

Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth

Nov 24

Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement

Oct 14
Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement

Is Alkermes (NASDAQ:ALKS) A Risky Investment?

Sep 17
Is Alkermes (NASDAQ:ALKS) A Risky Investment?

Alkermes: Fairly Valued After Post-Earnings Bump

Jul 28

Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Jul 26
Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

Jul 04
Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

The Bottom Fishing Club: Alkermes Has Great Value And Safety

May 17

Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

May 08
Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Apr 09

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Apr 08
Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet

Jan 26

Alkermes upgraded to neutral at BofA on improved risk/reward outlook

Oct 14

Alkermes holder Sarissa Capital says it may look to increase its stake

Oct 07

Alkermes: Nothing Stands Out As Interesting

Sep 26

Alkermes initiated at neutral at Piper Sandler as company in transition

Aug 16

Alkermes Q2 2022 Earnings Preview

Jul 26

Earnings and Revenue Growth Forecasts

NasdaqGS:ALKS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,47923046841311
12/31/20251,41619328732914
12/31/20241,50732833439914
9/30/20241,505387315356N/A
6/30/20241,508386327374N/A
3/31/20241,726570394444N/A
12/31/20231,663519353401N/A
9/30/20231,591455254295N/A
6/30/20231,462300159196N/A
3/31/20231,121-9-59-22N/A
12/31/20221,112-33-1721N/A
9/30/20221,132-1291451N/A
6/30/20221,173-94102133N/A
3/31/20221,201-62140169N/A
12/31/20211,1747673102N/A
9/30/20211,129-92112138N/A
6/30/20211,100-6388115N/A
3/31/20211,044-954878N/A
12/31/20201,039-1114183N/A
9/30/20201,171-74-1158N/A
6/30/20201,162-126-5328N/A
3/31/20201,194-139-7810N/A
12/31/20191,171-197-1972N/A
9/30/20191,074-2011491N/A
6/30/20191,067-1831993N/A
3/31/20191,092-17374148N/A
12/31/20181,094-1393099N/A
9/30/20181,054-139575N/A
6/30/20181,023-141N/A61N/A
3/31/2018937-152N/A6N/A
12/31/2017903-158N/A19N/A
9/30/2017842-169N/A-9N/A
6/30/2017804-196N/A-14N/A
3/31/2017781-200N/A-20N/A
12/31/2016746-208N/A-64N/A
9/30/2016695-257N/A-69N/A
6/30/2016668-275N/A-113N/A
3/31/2016624-274N/A-100N/A
12/31/2015628-227N/A-40N/A
9/30/2015640-127N/A-29N/A
6/30/2015648-86N/A-7N/A
3/31/2015650-36N/A17N/A
12/31/2014619-30N/A11N/A
9/30/2014598-42N/A36N/A
6/30/2014578-10N/A85N/A
3/31/2014563-7N/A89N/A
12/31/201359621N/A148N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALKS's earnings are forecast to decline over the next 3 years (-12.6% per year).

Earnings vs Market: ALKS's earnings are forecast to decline over the next 3 years (-12.6% per year).

High Growth Earnings: ALKS's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ALKS's revenue is expected to decline over the next 3 years (-0.7% per year).

High Growth Revenue: ALKS's revenue is forecast to decline over the next 3 years (-0.7% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ALKS's Return on Equity is forecast to be low in 3 years time (15.9%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 14:56
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alkermes plc is covered by 36 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Robert HazlettBMO Capital Markets U.S. (Historical)
Jason Matthew GerberryBofA Global Research